Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial
JCO Global Oncology · 2024
DOI: 10.1200/go.24.00059 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Kumar Prabhash und 30 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Tata Memorial Hospital, Mumbai, India. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Cetuximab, Head and Neck Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer, with approximately 225,419 new cases with over 125,000 deaths annually in India. This trial compared the efficacy and safety of biosimilar cetuximab versus innovator cetuximab (IC) in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic SCCHN. METHODS This phase III trial is a multicenter, randomized, double-blind and parallel group study performed in Indian patients with recurrent locoregional or metastatic SCCHN. Patients were randomly assigned in 2:1 ratio to receive biosimilar cetuximab and IC in combination with cisplatin and fluorouracil via intravenous infusions. The primary end points were disease control rate (DCR) and overall response rate (ORR) as per response evaluation criteria in solid tumors version 1.1. The secondary end points included pharmacokinetics (PK), immunogenicity, safety, and tolerability. RESULTS Of 180 patients enrolled, 120 patients received biosimilar cetuximab and 60 patients received IC treatment. No significant statistical difference was observed in the primary outcomes between two groups. Treatment difference in DCR and ORR response was found to be –5.21 (90% CI, –8.94 to –1.48) and –4.79 (90% CI, –19.42 to 9.84), respectively, indicating noninferiority to reference product. The incidence of treatment-emergent adverse events (AEs; biosimilar cetuximab: 89.2% v IC: 91.7%; P = .8364) and serious AEs (biosimilar cetuximab: 23.3% v IC: 13.3%; P = .0603) and PK parameters were comparable between treatment groups. The immunogenicity findings showed higher incidence of anticetuximab antibodies in the biosimilar cetuximab group compared with the IC group at the end of Study. CONCLUSION The findings of this study demonstrated noninferiority along with comparable PK, safety, and immunogenicity of biosimilar cetuximab and IC in patients with recurrent or metastatic SCCHN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Tata Memorial Hospital, Mumbai, India.
- Deenanath Mangeshkar Hospital & Research Center, Pune, India.
- Medical Oncology, Sriram Cancer Center, Mahatma Gandhi Medical College Hospital, Jaipur, India.
- Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
- KEM Hospital and Research Center, Pune, India.
- Kolhapur Cancer Center, Kolhapur, India.
ORCID-Profile: Kumar Prabhash, Hemant Malhotra, Atul Sharma, Nilesh Dhamne, Chandan K Das, Suhas Aagre, Vanita Noronha, Nandini Menon, Amol Aiwale
Zitieren
APA
Prabhash, K., Deshmukh, C., Malhotra, H., Sharma, A., Jain, M., Dhamne, N., Nagarakar, R., Ganesan, P., Mahobia, V. K., Das, C. K., Kumar, R., Shivanna, P. S., Avaronnan, M. P., Chaithanya, P. K., Chaudhary, V., Singh, K., Aagre, S., Ravishankar, B., Mehta, D., …, & Aiwale, A. (2024). Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial. JCO Global Oncology. https://doi.org/10.1200/go.24.00059
Vancouver
Prabhash K, Deshmukh C, Malhotra H, Sharma A, Jain M, Dhamne N, et al. Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial. JCO Global Oncology. 2024. doi:10.1200/go.24.00059
BibTeX
@article{Prabhash2024,
author = {Prabhash, Kumar and Deshmukh, Chetan and Malhotra, Hemant and Sharma, Atul and Jain, Minish and Dhamne, Nilesh and Nagarakar, Rajnish and Ganesan, Prasantha and Mahobia, Vijay K and Das, Chandan K and Kumar, Rejnish and Shivanna, Prakash S and Avaronnan, Manu P and Chaithanya, Puligundla K and Chaudhary, Vaibhav and Singh, Kartar and Aagre, Suhas and Ravishankar, Bellala and Mehta, Dhruv and Shilpa, Kandipalli and Maniar, Vashishth and Chatterjee, Koushik and Majumdar, Saroj D and Dana, Rohitashwa and Noronha, Vanita and Menon, Nandini and Sharma, Akhilesh and Pawar, Roshan and Shahavi, Vinayaka and Yadav, Rajiv and Aiwale, Amol},
title = {Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go.24.00059}
}
EUVIMED